This is the authors' abstract. We don't add key points for this paper.
SFN improves the cytotoxicity of CAR-T cells by modulating the PD-1/PD-L1 pathway, which may provide a promising strategy for the combination of SFN with CAR-T cells for cancer immunotherapy.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Shen et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: